OBJECTIVES: We investigated the association between serum levels of C-reactive protein (CRP), a marker of inflammation, and the severity of psychopathology and cognitive impairment in schizophrenia. METHODS: We measured the levels of CRP in N=413 individuals with schizophrenia. Symptom severity was evaluated with the Positive and Negative Syndrome Scale (PANSS) and cognitive functioning with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RESULTS: The individuals with CRP >or=5.0 mg/microl had significantly lower RBANS cognitive scores than those with CRP <5.0 mg/microl (F=8.07, p<.005). However the CRP groups did not differ in the severity of positive, negative, or general PANSS symptoms (all p>.2). CONCLUSIONS: Elevated serum levels of C-reactive protein in schizophrenia are associated with the severity of cognitive impairment but not of psychiatric symptoms. The long term consequences of elevated levels of CRP require further investigation.
OBJECTIVES: We investigated the association between serum levels of C-reactive protein (CRP), a marker of inflammation, and the severity of psychopathology and cognitive impairment in schizophrenia. METHODS: We measured the levels of CRP in N=413 individuals with schizophrenia. Symptom severity was evaluated with the Positive and Negative Syndrome Scale (PANSS) and cognitive functioning with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RESULTS: The individuals with CRP >or=5.0 mg/microl had significantly lower RBANS cognitive scores than those with CRP <5.0 mg/microl (F=8.07, p<.005). However the CRP groups did not differ in the severity of positive, negative, or general PANSS symptoms (all p>.2). CONCLUSIONS: Elevated serum levels of C-reactive protein in schizophrenia are associated with the severity of cognitive impairment but not of psychiatric symptoms. The long term consequences of elevated levels of CRP require further investigation.
Authors: Brian H Shirts; Konasale M Prasad; Michael F Pogue-Geile; Faith Dickerson; Robert H Yolken; Vishwajit L Nimgaonkar Journal: Schizophr Res Date: 2008-09-17 Impact factor: 4.939